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ABSTRACT 
In present work Colon targeting drug delivery system was developed for Busulfan an anticancer drug by using combination of delayed systems 
one is pH dependant and other is time dependant delayed system.  Rapid release core tablet (RRCT) formulations were prepared using Busulfan 
drug with different disintegrating agents in different concentrations. The pre-compression and post-compression parameters of all 
formulations were determined and the values were found to be satisfactory. From the In-vitro dissolution studies, F6 formulation with 12% 
Hydroxy propyl cellulose (HPC) was the best formulation. For optimized RRCT formulation press coat was done by using Xanthum Gum and 
Ethyl Cellulose (EC) in different ratios. Press coated tablet delays the drug release up to 8 hours based on the nature and concentrations of the 
polymer. Each press coated tablet was coated using enteric solution made of HPMC phthalate, Myvacet and color dissolve d in ethanol. Enteric 
press coated tablets (EPCT) were delayed drug release up to 2hrs in fed condition due to pH dependant delayed system.  Based on dissolution 
studies of EPCT formulations, C3OPF formulation was optimized and showed delayed release pattern in a much customized manner. As a result 
of this study it may be concluded that the colon targeted drug delivery tablets using a combination of two polymers in optimi zed concentrations 
can be used to increase the delayed action of drug release to deliver the drug in a delayed manner.  
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1. INTRODUCTION 
Oral administration is that the most well liked 
route for systemic effects because of its simple uptake and 
patient compliance. Additionally, solid oral delivery systems 
don't need sterile conditions and are so, less expensive to 
manufacture. Colon is being extensively investigated as a 
drug delivery site. Oral colon-specific drug delivery 
system (CDDS)1 has been developed by means of 
combination of one or more controlled release 
mechanisms. The arrival of an oral dosage form at the 
colon is determined by the rate of gastric emptying and the 
small intestine time. The presence of food generally 
increases residence time and in some cases with regular 
feeding, dosage forms have been reported to reside in the 
stomach for periods in excess of 12 hours. Small intestine 
transit is surprisingly constant at 3-4 hours and appears 
to be independent of the dosage form and fasted or fed 
state. Therefore a dosage form could take from as little as 
4 hours to longer than 12 hours to arrive at the colon 
following oral administration. In healthy and young adult 
male, dosage forms such as capsule and tablets pass 
through the colon in approximately 20-30 hours, although 
the transit time of a few hours to more than 2 days can 
occur.  
Three types of approaches to colon specific drug 
delivery: pH dependent delivery2, timed release dosage 
forms and delivery based on metabolic activity of colonic 
bacteria. Timed-controlled formulations have also been 
prepared using water insoluble ethyl cellulose and 
swellable polymer. Each of the formulations consisted of 
a rapid releasing core with drug, swellable and water 
insoluble polymer. The swelling polymer absorbs liquid 
and ethylcellulose coat disintegrated as the core swells.  
 Busulfan is a cell cycle non-particular alkylating 
anticancer drug. Busulfex and Myleran are two well-known 
trade names for this drug. Busulfan used in alone or 
combination with cyclophosphamide as conditioning agent 
prior to chronic myelogenous leukemia and other 
lymphomas. This drug recently used to study the role of 
serotonin in liver regenerations. Busulfan is chemotherapy 
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drug used to treat blood cancer before stem cell transplant3. 
2. METHODOLOGY 
2.1 Materials: Busulfan drug is gifted by Chandra labs, 
Hyderabad. Micro crystalline cellulose (Avicel pH 102), 
Hydroxyl propyl cellulose (HPC) and Cross carmellose 
sodium (CCS Ac-Di-Sol) were purchased from S.D fine 
chemicals Ltd, Mumbai. Sodium starch glycolate (SSG) was 
purchased from Mylan chemicals Ltd, Mumbai. Ethyl 
cellulose (EC), HPMC Phthalate-55 and Xanthum gum were 
purchased form ESSEL fine chemicals, Mumbai. Other 
chemicals and reagents were laboratory standards. 
2.2 Equipment: Electronic balance (Citizen, India), Tablet 
compression machine (Cadmach single punch machine), 
Hardness tester (Monsanto hardness tester), Dissolution 
apparatus (Lab India), Disintegration apparatus (Campbell 
Electronics), Friability test apparatus (Riche Rich), UV-
Visible spectrophotometer (Shimadzu UV-1601, Japan), 
Fourier transformer infrared spectrophotometer (Bruker). 
2.3 Analytical Methods4 
2.3.1 Estimation of Busulfan (API): Busulfan drug was 
studied for physical description like colour, odour and also 
estimated melting point of pure drug. 
2.3.2 Determination of λ max for Busulfan: On the basis of 
preliminary identification test, it was concluded that the 
drug complied the preliminary identification.  
2.3.3 Preparation of calibration curve in 0.1N HCL 
Preparation of Standard Stock solution: 100 mg of 
Busulfan was dissolved in 100 ml 0.1N HCL to give a 
concentration of (1000μg/ml). 
Sample Preparation and Scanning: 10ml of standard stock 
solution was diluted to 100 ml with 0.1N HCL respectively to 
get 100 μg/ml stock solutions. From this stock solution, 
aliquots of 2, 4, 6, 8, 10 ml were pipetted out and made up to 
100 ml in order to get concentration ranging from 2-10 
μg/ml. The absorbance of the solution was measured by UV 
spectrophotometry. 
2.3.4 Preparation of calibration curve in 6.8 phosphate 
buffer5 
Standard solution:  100 mg of Busulfan was dissolved in 
acetonitrile and made up to a volume of 100 ml with pH 6.8 
buffer solution to give a concentration of 1 mg/ ml (1000 
µg/ml).  
Sample preparation and scanning: From standard 
solution take 1 ml of solution in 100 ml of pH 6.8 buffer 
solution to produce the 10 µg/ml concentration .different 
aliquots of solutions were taken to produce 2, 4, 6, 8 and 10 
µg/ml concentrations. The absorbance of prepared solution 
of Busulfan was measured in UV/visible spectrophotometer 
against pH 6.8 buffer solutions as blank.  
2.4 Pre-compression flow parameters for RRCT6 
2.4.1 Angle of Repose: The flow property was determined 
by measuring the Angle of Repose. In order to determine the 
flow property, the Angle of Repose was determined. It is the 
maximum angle that can be obtained between the free 
standing surface of a powder heap and the horizontal. 
Angle of repose= tan-¹ (h/r) 
where, h = height of a pile (2 cm), r = radius of pile base. 
2.4.2 Bulk density (BD): Bulk density measuring the 
volume of known mass of powder sample and it is passed 
into the graduated cylinder and the ratio of given mass of 
powder and its bulk volume is known as bulk density. 
Bulk density = M / V0 
Where, M= mass of the powder, V0=bulk volume of the 
powder. 
2.4.3 Tapped density (TD): Weigh accurately a quantity of 
powder and transferred into a measuring cylinder and note 
down the volume as V0. Now the measuring cylinder is fixed 
to density determination apparatus, and tapped for 500 
times until no further volume changes is observed then note 
down the volume Vr.  
Tap density = M / Vr 
Where, M = mass of the powder, Vr = final tapping volume of 
the powder. 
2.4.4 Compressibility index and Hausner ratio: Bulk 
density and tapped density values were used to calculate the 
compressibility index and hausner ratio following is the 
equation: 
Compressibility index (CI) = 100 × (TD-BD) / TD 
Hausner ratio = TD/BD 
2.5 Drug-Excipient compatibility studies 
Drug and Excipient compatibility studies were performed 
for pure drug and final blend used in enteric press coated 
tablet formulation using FTIR. 
2.6 Formulation of Rapid release core tablets (RRCT)7 
Direct compression method is used for the preparation of inner 
core tablets required quantities ingredients like Busulfan, 
MCC, CCS, SSG, HPC, Starch as shown in the table were taken, 
make them into a mixture and subjected to dry blending for 20 
minutes followed by addition of Magnesium Stearate and Talc. 
The   mixtures were then further blended for 10 min., 200 mg 
of resultant powder blend was, punched to obtain the core 
tablet.
 
Table no.1 Formulation of Busulfan RRCT 
Ingredients(%) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Busulfan (mg) 2 2 2 2 2 2 2 2 2 
Starch  10 10 10 10 10 10 10 10 10 
 CCS 4 8 12 - - - - - - 
HPC - - - 4 8 12 - - - 
SSG   - - - - - - 4 8 12 
Magnesium stearate 2 2 2 2 2 2 2 2 2 
MCC Qs Qs Q s Qs Qs Qs Q s Qs Qs 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Total weight 200 200 200 200 200 200 200 200 200 
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2.7 Evaluation of post compression parameters8                   
2.7.1 Size and Shape: Thickness is the only variable to 
calculate the size and shape of a tablet. Micro - meter is the 
device which is used to determine the thickness of the tablet. 
Controlled variation for tablet thickness lies within a ± 5% 
standard value. 
2.7.2 Weight variation test: 20 tablets were weighed 
individually. Average weight was calculated from the total 
weight of all tablets. The individual weights were compared 
with the average weight. The percentage difference in the 
weight variation should be within the permissible limits 
(+5%). The percent deviation was calculated using the 
following formula. 
             Individual weight – Average weight 
% Deviation = -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- X 100 
Average weight 
2.7.3 Hardness: Tablets require a certain amount of 
strength or hardness and resistance to friability, to 
withstand mechanical shocks of handling in manufacture, 
packing and shipping. The hardness of tablet was measured 
by Monsanto hardness tester. The tablets from each batch 
were used for hardness studies and results are expressed in 
Kg/cm2. 
2.7.4 Friability: Weigh about 10 collectively tablets from 
each batch and place them in the Roche friabilator chamber. 
Now they were subjected to rolling, a free fall in the chamber 
from a height of 6cm which is rotated at a rate of 25 rpm. 
Repeat the procedure till the completion of 100 rotations (4 
minutes), and now the tablets were taken out from the 
friabilator and note their weight. The percentage friability 
was determined by the formula: 
% Friability = (W1-W2) / W1 X 100 
Where, W1 = Weight of tablets before test, W2 = Weight of 
tablets after test 
2.7.5 In-vitro release studies for RRCT9: Tablet was 
introduced into the basket of the instrument (USP-II, 37 + 
0.5°C) which is rotated at 50 rpm for time period of 1 hr. 
Withdraw 5 ml of sample aliquots with predetermined time 
intervals (5, 10, 15, 20, 30, 45 and 60min) and is replaced by 
pH6.8 phosphate buffer solutions. Determine the amount of 
drug in the withdrawn samples.  
2.8 Preparation of Enteric press coated tablets (EPCT) 
The optimized core tablets were press-coated with 250 mg 
of mixed blend/granules. Different proportions of barrier 
layer material (1:1, 0:1, 1:0, 4:2 and 2:4) was weighed and 
transferred into the die then the core tablet was placed 
manually at the centre. The remaining mg of the barrier 
layer materiel was added into the die and punched in to a 
12mm die at a pressure of 5tons for 3min using hydraulic 
press. Press coated tablets were enteric coated using spray 
drying method and enteric coated solution was prepared as 
mentioned in table no.3. 
 
Table no.2 Polymer ratio for press coated tablets: 
Polymer (mg) C1OPF C2 OPF C3 OPF C4 OPF C5 OPF 
Xanthun gum 250 125 166.6 83.4 0 
EC 0 125 83.4 166.6 250 
OPF- Optimized RRCT Formulation 
 
Table no.3 Enteric coated solution formula 
Ingredients (mg) 
HPMC phthalate 55 15.17 
Myvacet 1.52 
Ferric oxide (red) 1.58 
Ethanol Qs 
 
2.9 In-vitro Dissolution methods for EPCT9  
In –vitro Dissolution  studies  of  oral colon targeted drug  
delivery  systems  was done with  the conventional paddle 
method and dissolution was performed at 37  ± 0.5°C using 
0.1N HCL in USP II paddle method at 50 rpm for first two 
hours and replaced with pH6.8  phosphate buffer. Samples 
were withdrawn for every one hour up to 10hrs and replace 
the same with new fresh dissolution medium to achieve sink 
condition. The samples were analysed using UV 
spectrophotometer.  
 
2.10 Release kinetics for optimized EPCT10 
To analyse the mechanism for the release and release rate 
kinetics of the dosage form, the data obtained was fitted in 
to Zero order, First order, Higuchi matrix, Peppas and 
Hixson Crowell model. In this by comparing the r-values 
obtained, the best-fit model was selected. 
3. RESULTS AND DISCUSSION 
3.1 Analytical studies of Busulfan (API) 
3.1.1 Description of Busulfan: 
Table no.4 Estimation of Busulfan (API) 
Description Color - A white or almost white 
crystalline powder 
Odor – Free of odor 
Solubility Acetonitrile – Freely soluble 
Methanol – Slightly soluble 
Water – Very slightly soluble 
Melting point 106 – 1070C 
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3.1.2 Scanning of Busulfan (API):  
 
Figure no.1 UV-Visible spectrum observed at 260nm 
 
3.1.3 Calibration curves of Busulfan: 
A         B  
Figure no.2 Standard graph of Busulfan in A) 6.8pH phosphate buffer B) 0.1N HCL 
 
3.1.4 Drug excipient compatibility studies (FTIR): 
C    
D     
Figure no.3 FTIR of C) Busulfan drug D) EPCT blend 
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3.2 Flow properties of RRCT: 
Table no.5 Flow parameters of RRCT 
Formulation B.D(gm/ml) T.D(gm/ml) C.I (%) H.R Angle of reposen(0) 
F1 0.31 0.36 13.88 1.16 27.26±0.12 
F2 0.36 0.41 12.19 1.13 25.13±0.08 
F3 0.32 0.37 13.51 1.15 26.27±0.02 
F4 0.31 0.35 11.92 1.12 27.23±0.25 
F5 0.35 0.41 14.63 1.17 26.78±0.11 
F6 0.38 0.43 11.42 1.13 25.14±0.15 
F7 0.37 0.42 11.90 1.13 25.91±0.16 
F8 0.32 0.38 15.78 1.18 26.24±0.21 
F9 0.34 0.39 12.82 1.14 25.12±0.14 
 
3.3 Evaluation of RRCT formulations 
3.3.1 Characterization of RRCT formulations:  
Table no.6 Characterization of Busulfan RRCT 
Where n=3  
3.3.2 Dissolution studies of RRCT formulations 
E  
F  
G  
Figure no.4 Dissolution graphs for RRCT formulations F1-F9 (E, F & G) 
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F7
F8
F9
S.  
No 
Physical  
parameter 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 
Weight 
variation 
200± 
1.517 
199± 
1.519 
197± 
1.521 
199± 
3.241 
199± 
1.518 
201± 
1.518 
200± 
1.517 
199± 
3.242 
201± 
2.020 
2 
Hardnessn 
(Kg/cm2) 
4.5± 
0.1 
4.62±0.
03 
4.28±0.
04 
4.51±0.
04 
4.54± 
0.05 
4.5± 
0.05 
4.28± 
0.05 
4.49± 
0.05 
4.19±0.
2 
3 
Thicknessn 
(mm) 
2.4± 
0.1 
2.5± 
0.05 
2.3± 
0.1 
2.4± 
0.1 
2.5± 
0.05 
2.5± 
0.05 
2.46± 
0.05 
2.62± 
0.11 
2.76±0.
05 
4 Friability(%) 0.35 0.34 0.36 0.35 0.34 0.33 0.34 0.35 0.35 
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From RRCT dissolution results F6 formulation was taken for further studies as optimized RRCT formulation containing 
Busulfan drug. 
3.4 Evaluation of EPCT formulations 
3.4.1 Characterisation of EPCT formulations: 
Table no.7 Evaluation parameters for EPCT 
S.no Physical parameters C1OPF C2OPF C3OPF C4OPF C5OPF 
1 Weight variationn (%) 501.114 504±0.047 502±0.058 504±0.121 506±0.031 
2 Hardnessn (Kg/cm2) 7.2±0.05 7.6±0.010 7.5±0.09 7.4±0.02 7.5±0.06 
3 Thicknessn (mm) 4.1±0.011 3.8±0.07 4.0±0.014 3.7±0.011 4.0±0.06 
4 Friabilityn (%) 0.42±0.001 0.44±0.003 0.45±0.004 0.48±0.004 0.45±0.005 
Where n=3  
3.4.2 Dissolution studies for EPCT formulations: 
Table no.8 Dissolution profile of EPCT of Busulfan 
Time in hrs Enteric Press coat Formulation code 
 C1OPF C2OPF C3OPF C4OPF C5OPF 
Dissolution medium - 0.1NHCl 
1 0 0 0 0 0 
2 0 0 0 0 0 
Dissolution medium - pH 6.8 Phosphate Buffer 
3 4 7.4 4.9 3.6 4.6 
4 5 14.8 9.7 7.4 9.2 
5 11 29.7 25.7 9.8 13 
6 15 41.2 41.6 14.8 16 
7 20 58.7 58.2 29 24 
8 29 77.9 72.7 46 35 
9 46 89.6 85.9 74 47 
10 68 - 94.6 90 74 
 
From EPCT formulations dissolution results C3OPF formulation was selected among all formulations in which 4 parts of 
Xanthum and 2 parts of EC were present as press coating material based on the percentage of drug release up to 10 hrs. 
3.5 In-vitro release kinetic studies 
The kinetic data analysis of optimized formulation reached higher coefficient of determination with the First order (R2 = 0.938). 
From the coefficient of determination and release exponent values, it can be suggested that the mechanism of drug release 
follows Korsmeyer-Peppas model along with non-Fickian diffusion mechanism which leading to the conclusion that a release 
mechanism of drug followed combination of diffusion and spheres erosion. 
H   
I   
J    
K    
Figure no.5 Release kinetic graphs of H) zero order I) first order J) higuchi model K) korsmeyer model 
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4. CONCLUSION 
Colon specific drug delivery was the most preferable ones in 
targeting site-specific drug release in the colon with 
enhanced local or systemic effects. Direct compression 
method is used for core tablet preparation and all the 
formulations were evaluated for pre compression 
parameters like density, flow properties and post 
compression parameters like hardness, friability, weight 
variation and In-vitro drug release. Optimized core tablet F6 
formulation was press coated using polymers Xanthum gum 
and EC in different ratios to delay the release of core tablet. 
Enteric press coated tablets were prepared by spray drying 
enteric coating solution over press coated tablets. Finally 
C3OPF enteric coated formulation containing Xanthum gum 
and EC in 4:2 ratios as press coat was optimized based on 
dissolution studies. Drug release kinetic study of optimized 
formulation indicates drug release in present study is 
combination of diffusion and sphere erosion.  
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